In patients with NSTE ACS, fondaparinux was not inferior to enoxaparin in reducing the occurrence of death, MI or refractory ischemia at 9 days, and was superior to enoxaparin in reducing death ...

While fondaparinux has been available for nearly a decade, its use has not been nearly as extensive as the use of LMWHs. Thus, clinical experience with this agent and outcomes data are far more ...